

REMARKS


Upon entry of the amendments, claims 1, 6-12 and 23-34 will be present in the application for examination. Cancellation of any original claims should not be construed as abandonment of their subject matter, as applicants are reserving the right to again present claims of a similar scope in this or a continuing application.

The pending claims are substantially the same as those determined to be allowable in prior application Serial No. 09/616,866 and have been patterned generally after the claims to loratadine formulations in applicants' U.S. Patent 6,132,758.

Also being submitted at this time is an information disclosure, consisting of a Form PTO-1449 having twelve documents listed and a copy of each document. Note that these copies are the best available at this time; any markings on the documents should be disregarded, since marking may have been done for a purpose totally unrelated to the present application. The return of an initialed copy of the form, indicating consideration of the documents, is requested.

As all of the pending claims are believed to be patentable, an early notification of their allowance is respectfully solicited. However, if any minor matters remain to be resolved before disposition of the application, kindly contact the undersigned to arrange for a telephonic or personal interview.

Respectfully submitted,



Robert A. Franks
Attorney for Applicants
Reg. No. 28,605

Patent Department (K-6-1, 1990)
Schering-Plough Corporation
2000 Galloping Hill Road
Kenilworth, New Jersey 07033-0530
Telephone (908) 298-2908
Facsimile (908) 298-5388



CLAIM VERSION WITH MARKINGS TO SHOW AMENDMENTS MADE

1. (Amended) An antihistaminic syrup formulation [containing] comprising descarboethoxyloratadine and about 0.05 to about 5 mg/mL of an aminopolycarboxylic acid[, including salts] or a salt thereof.

PA